|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.91/-0.19
|
企业价值
36.31M
|
资产负债 |
每股账面净值
-0.61
|
现金流量 |
现金流量率
--
|
损益表 |
收益
530.00K
|
每股收益
1.04
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/04/25 18:02 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies. |